Development of nanoscale drug delivery systems of dihydroartemisinin for cancer therapy: A review

Wong, Ka Hong; Yang, Donglin; Chen, Shanshan; He, Chengwei; Chen, Meiwan

doi:10.1016/j.ajps.2022.04.005

Cited by 28 publications

(13 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Through system Xc -, ferroptosis plays an important role in modulating the response of Glioma to radiotherapy, immunotherapy, and TMZ, addressing the problem of poor safety and low utilization of traditional therapeutic agents that are not available, Ferroptosis offers additional advantages. Both artemisinin and its derivatives (e.g., dihydroartemisinin and artesunate), the active ingredients extracted from the Chinese medicine Artemisia annua, can induce ferroptosis in tumor cells by enhancing heme oxygenase-1 expression and intracellular pools of unstable iron (74). Dihydroartemisinin can act as an inhibitor of GPX4 and system Xc-, increasing the accumulation of lipid peroxides in glioblastoma cells and inducing ferroptosis (75).…”

Section: Gliomamentioning

confidence: 99%

Ferroptosis-based drug delivery system as a new therapeutic opportunity for brain tumors

Yao

Chen

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

The brain tumor is a kind of malignant tumor with brutal treatment, high recurrence rate, and poor prognosis, and the incidence and death rate is increasing yearly. Surgery is often used to remove the primary tumor, supplemented by radiotherapy and chemotherapy, which have highly toxic side effects. Therefore, there is an urgent need to explore new strategies, methods, and technologies that can genuinely improve the treatment of brain tumors. Ferroptosis differs from traditional apoptosis’s morphological and biochemical characteristics, and ferroptosis possesses its unique characteristics and mechanisms, opening up a new field of ferroptosis treatment for cancer. It has been found that there is a close relationship between ferroptosis and brain tumors, and a novel nano-drug delivery system based on ferroptosis has been used for the ferroptosis treatment of brain tumors with remarkable effects. This review firstly analyzes the characteristics of ferroptosis, summarizes the mechanism of its occurrence and some factors that can be involved in the regulation of ferroptosis, introduces the potential link between ferroptosis and brain tumors, and clarifies the feasibility of ferroptosis in the treatment of brain tumors. It then presents the ferroptosis nano drug delivery systems developed under different metabolic pathways for ferroptosis treatment of brain tumors. Finally, it summarizes the current problems and solutions of ferroptosis nano drugs for brain tumor treatment, aiming to provide a reference for developing ferroptosis nano drugs against brain tumors.

show abstract

Section: Gliomamentioning

confidence: 99%

Ferroptosis-based drug delivery system as a new therapeutic opportunity for brain tumors

Yao

Chen

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…DHA gives high plasma concentration and is easy to synthesize. Thus, it is preferred as a malaria drug 2,9 . Extraction and isolation of artemisinin and its derivatives have been conducted by various methods 10–12 .…”

Section: Introductionmentioning

confidence: 99%

“…Thus, it is preferred as a malaria drug. 2,9 Extraction and isolation of artemisinin and its derivatives have been conducted by various methods. [10][11][12] A conventional extraction method of A. annua is conducted by liquid extraction using organic solvent such as hexane and petroleum ether.…”

mentioning

confidence: 99%

Core–shell magnetic‐modified molecular imprinted polymer (Fe₃O₄@SiO₂@MIP) for dihydroartemisinin recognition and separation

Fauzia¹,

Andreas²,

Muzdalifah³

et al. 2023

Polymers for Advanced Techs

View full text Add to dashboard Cite

Dihydroartemisinin (DHA) is an artemisinin derivative compounds that employs as malaria drug. Extraction and purification artemisinin derivatives by liquid extraction utilize organic solvent and results in mixtures of compounds requiring further purification process. In this study, core-shell magnetic molecular imprinted polymer (Fe 3 O 4 @SiO 2 @MIP) has been synthesized for DHA isolation. Methacrylic acid (MAA) and ethylene glycol dimethacrylate (EGDMA) were employed as monomer and cross-linker, respectively. Fe 3 O 4 was modified by tetraethyl orthosilicate (TEOS) to enhance stability and prevent aggregation. Nonimprinted polymer (Fe 3 O 4 @SiO 2 @NIP) was also prepared as a comparison. The Fourier transform infrared (FTIR) represented O O stretching of O O C bond (1,2,4-trioxane ring) at 825 cm À1 denoting that DHA has been successfully attached to MIP. Meanwhile, the morphology of Fe 3 O 4 @SiO 2 @MIP and Fe 3 O 4 @SiO 2 @NIP revealed uniform spherical-like form particle due to core-shell magnetic modification. The Brunaeur-Emmett-Teller (BET) revealed S BET of Fe 3 O 4 @SiO 2 @MIP and Fe 3 O 4 @SiO 2 @-NIP was 70.16 and 19.56 m 2 g À1 , respectively. The prepared materials owned a superparamagentic behavior as indicated by narrow loop and low remanence and coercivity.The binding study indicated that Fe 3 O 4 @SiO 2 @MIP and Fe 3 O 4 @SiO 2 @NIP were achieved optimum condition at pH 4, contact time 90 min and initial concentration 8 mg L À1 with adsorption capacity (q exp ) 1.026 mg g À1 for Fe 3 O 4 @SiO 2 @MIP and 0.806 for Fe 3 O 4 @SiO 2 @NIP. The selectivity of Fe 3 O 4 @SiO 2 @MIP was more than 60% in all over the ratio. The prepared MIP exhibited good selectivity toward DHA with imprinting factor (IF) 2.14 and selectivity coefficient (α) 3.43. The percent adsorption of Fe 3 O 4 @-SiO 2 @MIP did not changed after three times adsorption-desorption cycles. The result exhibited that Fe 3 O 4 @SiO 2 @MIP could effectively be used for DHA separation.

show abstract

“…[2] Nanoscale drug delivery systems (NDDSs), such as polymeric nanoparticles (NPs), can overcome these limitations and enhance the anticancer properties of therapeutic agents. [3,4] Biomimetic proteins, such as lactoferrin (LF), an important member of the transferrin (TF) family, [5] can interact with low-density lipoprotein receptorrelated protein-1 (LRP1), an emerging blood-brain barrier (BBB) transcytosis carrier, to cross the BBB, thus delivering therapeutic drugs into brain tumor accumulate in mitochondria and disrupt mitochondrial homeostasis and subsequent mitochondrial dysfunction by photodynamic and photothermal effects, thus causing ROS accumulation and lipid peroxidation. DHA promotes iron overload and glutathione (GSH) consumption, which damages the antioxidant system and promotes ROS production via the Fenton reaction, ultimately leading to ferroptosis.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Drug Repurposing‐Based Brain‐Targeting Self‐Assembly Nanoplatform Using Enhanced Ferroptosis against Glioblastoma

Liang,

Li,

Tian

et al. 2023

Small

View full text Add to dashboard Cite

Glioblastoma (GBM), the most aggressive and lethal form of malignant brain tumor, is a therapeutic challenge due to the drug filtration capabilities of the blood‐brain barrier (BBB). Interestingly, glioblastoma tends to resist apoptosis during chemotherapy, but is susceptible to ferroptosis. Developing therapies that can effectively target glioblastoma by crossing the BBB and evoke ferroptosis are, therefore, crucial for improving treatment outcomes. Herein, a versatile biomimetic nanoplatform, L‐D‐I/NPs, is designed that self‐assembled by loading the antimalarial drug dihydroartemisinin (DHA) and the photosensitizer indocyanine green (ICG) onto lactoferrin (LF). This nanoplatform can selectively target glioblastoma by binding to low‐density lipoprotein receptor‐related protein‐1 (LRP1) and crossing the BBB, thus inducing glioblastoma cell ferroptosis by boosting intracellular reactive oxygen species (ROS) accumulation and iron overload. In addition, L‐D‐I/NPs have demonstrated the ability to effectively suppress the progression of orthotopic glioblastoma and significantly prolong survival in a mouse glioblastoma model. This nanoplatform has facilitated the application of non‐chemotherapeutic drugs in tumor treatment with minimal adverse effects, paving the way for highly efficient ferroptosis‐based therapies for glioblastoma.

show abstract

Development of nanoscale drug delivery systems of dihydroartemisinin for cancer therapy: A review

Cited by 28 publications

References 144 publications

Ferroptosis-based drug delivery system as a new therapeutic opportunity for brain tumors

Ferroptosis-based drug delivery system as a new therapeutic opportunity for brain tumors

Core–shell magnetic‐modified molecular imprinted polymer (Fe₃O₄@SiO₂@MIP) for dihydroartemisinin recognition and separation

Drug Repurposing‐Based Brain‐Targeting Self‐Assembly Nanoplatform Using Enhanced Ferroptosis against Glioblastoma

Contact Info

Product

Resources

About

Development of nanoscale drug delivery systems of dihydroartemisinin for cancer therapy: A review

Cited by 28 publications

References 144 publications

Ferroptosis-based drug delivery system as a new therapeutic opportunity for brain tumors

Ferroptosis-based drug delivery system as a new therapeutic opportunity for brain tumors

Core–shell magnetic‐modified molecular imprinted polymer (Fe3O4@SiO2@MIP) for dihydroartemisinin recognition and separation

Drug Repurposing‐Based Brain‐Targeting Self‐Assembly Nanoplatform Using Enhanced Ferroptosis against Glioblastoma

Contact Info

Product

Resources

About

Core–shell magnetic‐modified molecular imprinted polymer (Fe₃O₄@SiO₂@MIP) for dihydroartemisinin recognition and separation